Potential four‑miRNA signature associated with T�stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis

You, Lukuan; Wang, Jinliang; Zhang, Fan; Zhang, Jing; Tao, Haitao; Zheng, Xuan; Hu, Yi

doi:10.3892/mmr.2018.9663

Cited by 4 publications

(5 citation statements)

References 85 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have examined in silico the RNA sequencing data of pancreatic cancers from the TCGA database, in order to select miRNAs predicting survival length [73][74][75][76]. These publications are also not in agreement about the panels of predictive miRNAs for patient OS, which varied significantly in composition (Supplementary Table S2).…”

Section: Prognostic Role Of Mirnas Expression Profiles For Pdac Patient's Overall and Progression-free Survivalmentioning

confidence: 99%

Expression of selected microRNAs in pancreatic ductal adenocarcinoma: is there a relation to tumor morphology, progression, and patient’s outcome?

Szabó

Gürlich

Liberko

et al. 2020

neo

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) remains a disease with extremely poor prognosis and limited effective available treatment. Differential expression of miRNAs isolated from tumor tissue has been proposed as a marker for tumor diagnosis, progression, and prognosis. Nevertheless, the prognostic value of miRNAs expression in PDACs for patient outcome still remains unclear. Expression of 7 selected miRNAs, isolated from FFPE samples of 54 PDAC patients, was quantified using RT-qPCR. The relationship of miRNA expression levels with tumor histology, clinicopathological characteristics, patient overall survival (OS), and progress-free survival (PFS), was subsequently evaluated. Overexpression of miR-21, miR-155, and miR-210 was observed in PDACs (up to 72.62, 232.36, respectively), in comparison with non-neoplastic tissues. On the other hand, miR-96 and miR-217 were significantly downregulated in PDACs (up to one hundred times). No differences were, however, noticed between cancer and normal tissues for the expression levels of miR-148a and miR-196a. On the other hand, expression levels of all 7 miRNAs failed to demonstrate a significant correlation with parameters of tumor progression, such as tumor stage, grade, nodal involvement, perineural, and vascular invasion. The positive correlation of miR-210 levels was, however, observed with patient age (ρ=0.35). Additionally, miR-148a and miR-217 expressions have shown a positive association with tubular tumor growth pattern (ρ=0.39; ρ=0.28). The negative correlation of miR-148a values was also demonstrated with dissociative growth pattern and nuclear atypia (ρ=-0.30; ρ=-0.27). Finally, no statistically significant correlation could be demonstrated with the expression levels of all 7 tested miRNAs and PDAC patient survival; neither for OS nor for PFS (p>0.05). Our data have confirmed abnormal miRNAs expression in PDACs in comparison with adjacent non-neoplastic tissue. On the other hand, no correlation was discovered between miRNA expression and parameters of tumor progression. We have found a significant association between histologic tumor growth patterns and miRNA expression, making this work the first study, which analyses this aspect of PDAC. Finally, in our group of patients, no relationship of miRNA levels and patient prognosis could be demonstrated. Therefore, further investigation is required to evaluate the predictive and prognostic potential of miRNAs in a clinical setting.

show abstract

Section: Prognostic Role Of Mirnas Expression Profiles For Pdac Patient's Overall and Progression-free Survivalmentioning

confidence: 99%

Expression of selected microRNAs in pancreatic ductal adenocarcinoma: is there a relation to tumor morphology, progression, and patient’s outcome?

Szabó

Gürlich

Liberko

et al. 2020

neo

View full text Add to dashboard Cite

show abstract

“…The Illumina HumanWG-6 v3.0 expression beadchip (GPL6884) was used to produce the sequencing data. The goodSamplesGenes function in Weighted Gene Co-expression Network Analysis (WGCNA) was used to filter the samples and genes with too many missing entries and zero-variance genes [10].…”

Section: Gene Expression Data and Preprocessingmentioning

confidence: 99%

Identifying novel biomarkers of the pediatric influenza infection by weighted co-expression network analysis

Ghobadi

Mozhgani

Farzanehpour

et al. 2019

Virol J

View full text Add to dashboard Cite

Background: Despite the high yearly prevalence of Influenza, the pathogenesis mechanism and involved genes have not been fully known. Finding the patterns and mapping the complex interactions between different genes help us to find the possible biomarkers and treatment targets. Methods: Herein, weighted gene co-expression network analysis (WGCNA) was employed to construct a co-expression network among genes identified by microarray analysis of the pediatric influenza-infected samples. Results: Three of the 38 modules were found as the most related modules to influenza infection. At a functional level, we found that the genes in these modules regulate the immune responses, protein targeting, and defense to virus. Moreover, the analysis of differentially expressed genes disclosed 719 DEGs between the normal and infected subjects. The comprehensive investigation of genes in the module involved in immune system and viral defense (yellow module) revealed that SP110, HERC5, SAMD9L, RTP4, C19orf66, HELZ2, EPSTI1, and PHF11 which were also identified as DEGs (except C19orf66) have the potential to be as the biomarkers and also drug targeting for the treatment of pediatric influenza. Conclusions: The WGCN analysis revealed co-expressed genes which were involved in the innate immune system and defense to virus. The differentially expressed genes in the identified modules can be considered for designing drug targets. Moreover, modules can help to find pathogenesis routes in the future.

show abstract

“…Pancreatic ductal adenocarcinoma (PDAC) accounts for 90 percent of pancreatic cancer, with a 5-year survival rate under 5 percent 1. It is primarily caused by the biological characteristics of early recurrence and metastasis and the lack of early diagnosis methods 2,3. MicroRNAs (miRNAs), a sort of noncoding RNA, have approximately 22 ribonucleotide RNA sequences 3.…”

Section: Introductionmentioning

confidence: 99%

<p>MiR-193a-3p inhibits pancreatic ductal adenocarcinoma cell proliferation by targeting CCND1</p>

Chen¹,

Qiao²,

Chen³

et al. 2019

CMAR

View full text Add to dashboard Cite

Background: MicroRNAs (miRNAs) could modulate gene expression at the posttranscriptional level by promoting mRNA degradation or blocking mRNA translation, thus affecting the occurrence and development of cancer. Methods: In this work, qRT-PCR was conducted to detect the expression of miR-193a-3p and CCND1 . The ability of cell proliferation was evaluated via CCK-8 assay. Cell apoptosis and cell cycle distribution were detected by flow cytometry. Bioinformatic techniques were employed to research the regulatory relationship between miR-193a-3p and target genes. The relationship between miR-193a-3p and CCND1 was verified via dual-luciferase reporter assays. Results: MiR-193a-3p expression in pancreatic ductal adenocarcinoma (PDAC) tissue was significantly lower than in non-cancerous tissue. After overexpressing miR-193a-3p in PDAC cells, their multiplication ability was significantly inhibited, apoptosis was accelerated, and the cell cycle was blocked in the G1 and G2/M phases. CCND1 was confirmed to have a targeted relationship with miR-193a-3p. Moreover, CCND1 expression was significantly lower in PDAC cells with an overexpression of miR-193a-3p. Conclusions: MiR-193a-3p targeted CCND1 to suppress tumor growth in PDAC cells. MiR-193a-3p may function as a tumor inhibitor in PDAC development, which could offer a promising therapeutic and prognostic strategy for PDAC treatment.

show abstract

Potential four‑miRNA signature associated with T�stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis

Cited by 4 publications

References 85 publications

Expression of selected microRNAs in pancreatic ductal adenocarcinoma: is there a relation to tumor morphology, progression, and patient’s outcome?

Expression of selected microRNAs in pancreatic ductal adenocarcinoma: is there a relation to tumor morphology, progression, and patient’s outcome?

Identifying novel biomarkers of the pediatric influenza infection by weighted co-expression network analysis

<p>MiR-193a-3p inhibits pancreatic ductal adenocarcinoma cell proliferation by targeting CCND1</p>

Contact Info

Product

Resources

About